About this Research Topic
Cardiovascular disease (CVD) is one of the most important causes of death described in systemic lupus erythematosus (SLE) patients. They have a 5 to 6-fold higher CVD risk than the general population, and historically SLE is considered an independent CVD risk factor. Mortality in SLE patients presents a bimodal pattern, with an initial peak due to the clinical disease activity and a late peak attributable to the development of CVD. This mortality is characterized by the interaction of traditional and non-traditional CVD risk factors such as obesity, dyslipidemia, atherosclerosis, pro-inflammatory mediators, pharmacotherapy administered; and currently, dietary, microbiota dysbiosis, genetic, and epigenetic factors.
The goal of this Research Topic is to understand how traditional and non-traditional risk factors for CVD risk are associated with specific SLE clinical phenotypes or disease endotypes.
In this article collection, we aim to include original and review manuscripts that describe the role of CVD risk factors that are associated with clinical disease activity, organ damage, and comorbidities that impact SLE mortality outcomes, including but not limited to molecules and autoantibodies of lipid metabolism related to the lupus pattern of dyslipidemias, cytokines, hormones, pharmacotherapy, dietary components, gut microbiota, genetic variants (polymorphisms), and epigenetic factors that could provide an approach to understanding the mechanisms related to CVD risk in SLE. These studies may describe insights into how traditional and non-traditional CVD risk factors interact to establish a more novel understanding and characterization of CVD risk factors in SLE.
The goal of this Research Topic is to understand how traditional and non-traditional risk factors for CVD risk are associated with specific SLE clinical phenotypes or disease endotypes.
In this article collection, we aim to include original and review manuscripts that describe the role of CVD risk factors that are associated with clinical disease activity, organ damage, and comorbidities that impact SLE mortality outcomes, including but not limited to molecules and autoantibodies of lipid metabolism related to the lupus pattern of dyslipidemias, cytokines, hormones, pharmacotherapy, dietary components, gut microbiota, genetic variants (polymorphisms), and epigenetic factors that could provide an approach to understanding the mechanisms related to CVD risk in SLE. These studies may describe insights into how traditional and non-traditional CVD risk factors interact to establish a more novel understanding and characterization of CVD risk factors in SLE.
Keywords: lupus pattern of dyslipidemias, cytokines, hormones, pharmacotherapy, dietary components, gut microbiota, genetic variants (polymorphisms), epigenetic factors
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
